Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Pfizer : 4Q Sales Fall

share with twitter share with LinkedIn share with facebook
share via e-mail
01/28/2020 | 07:16am EST

By Dave Sebastian

Pfizer Inc. (PFE) reported lower fourth-quarter sales as it lost exclusivity in its pain drug Lyrica in 2019.

The New York drugmaker on Tuesday posted $12.69 billion in fourth-quarter sales, down from $13.98 billion in the prior year. Analysts polled by FactSet were expecting $12.69 billion in sales.

Sales in its Upjohn business, which includes Lyrica and anti-impotence pill Viagra, declined 32% to $2.16 billion for the quarter.

The company recorded net loss of $337 million, or 6 cents a share, compared with a loss of $394 million, or 7 cents a share, in the year-ago period.

Excluding one-time items, the company reported earnings of 55 cents a share. Analysts were looking for adjusted earnings of 58 cents a share.

Write to Dave Sebastian at dave.sebastian@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on PFIZER
02/19PFIZER INC. : - European Commission Approves VYNDAQEL, the First Treatment in th..
AQ
02/18PFIZER : Gets European Approval for Vyndaqel in ATTR-CM
DJ
02/18PFIZER : European Commission Approves VYNDAQEL®, the First Treatment in the EU f..
BU
02/14Sosei Heptares Operational Highlights and Consolidated Results for the 12 Mon..
AQ
02/13Dr. Mak Jawadekar Joins the Board of Directors of NanoViricides Inc
AQ
02/12ASTELLAS PHARMA : XTANDI Demonstrates Significant Improvement in Overall Surviva..
AQ
02/11PFIZER : XTANDI® (enzalutamide) Demonstrates Significant Improvement in Overall ..
PR
02/10Lilly, Roche Drugs Fail to Halt Inherited Form of Alzheimer's -- 2nd Update
DJ
02/10Lilly, Roche Drugs Fail to Halt Inherited Form of Alzheimer's -- Update
DJ
02/10Lilly, Roche Drugs Fail to Stymie Inherited Form of Alzheimer's
DJ
More news
Financials (USD)
Sales 2020 46 032 M
EBIT 2020 17 998 M
Net income 2020 12 525 M
Debt 2020 24 296 M
Yield 2020 4,14%
P/E ratio 2020 18,5x
P/E ratio 2021 17,7x
EV / Sales2020 4,84x
EV / Sales2021 4,70x
Capitalization 198 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 43,87  $
Last Close Price 35,85  $
Spread / Highest target 53,4%
Spread / Average Target 22,4%
Spread / Lowest Target 3,21%
EPS Revisions
Managers
NameTitle
Albert Bourla Chairman, Chief Executive & Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Mikael Dolsten Chief Scientific Officer
Lidia L. Fonseca Chief Technology Officer & EVP
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-7.53%198 398
JOHNSON & JOHNSON2.10%390 914
ROCHE HOLDING AG10.05%298 571
NOVARTIS3.81%217 737
MERCK AND COMPANY-9.30%210 018
NOVO NORDISK AS14.43%150 219